[144] Teladoc Health, Inc. SEC Filing

Rhea-AI Filing Summary

Teladoc Health, Inc. (TDOC) Form 144 shows an insider intends to sell 2,383 common shares acquired by restricted stock vesting and held for compensation. The shares are scheduled for sale through Fidelity Brokerage Services on the NYSE with an aggregate market value of $18,075.77 based on the filing. The filer reports prior small open-market sales during June totaling 6,532 shares for gross proceeds of $45,018.22. The securities were acquired and the vesting/compensation payment occurred on the same date indicated in the filing. The filing includes the signer’s representation that they are not aware of any undisclosed material adverse information about the issuer.

Positive

• Transaction transparency: The filing specifies acquisition method (restricted stock vesting), broker, and aggregate value.
• Small relative size: 2,383 shares versus 176,690,662 shares outstanding, indicating an immaterial stake reduction.
• Prior sales disclosed: Recent June sales totaling 6,532 shares and $45,018.22 proceeds are reported, supporting consistency.

Negative

• Insider sale disclosed: Planned disposition of vested shares may be viewed negatively by some market participants despite small size.

Insights

Financial Analyst

TL;DR: Insider plans to sell a small block of vested restricted shares; transaction size is immaterial to market capitalization.

This Form 144 documents a planned sale of 2,383 common shares acquired by restricted stock vesting and designated as compensation. The stated aggregate market value is $18,075.77 and the company’s outstanding share count in the notice is 176,690,662, which implies the transaction represents a de minimis fraction of outstanding equity. Prior disclosed sales by the same person in June totaled 6,532 shares for roughly $45,018, indicating routine monetization of vested compensation rather than a large, unexplained disposition. From a fundamentals perspective, these are routine insider liquidity events with negligible direct impact on valuation.

Corporate Governance Expert

TL;DR: The filing is a standard compliance disclosure for an insider sale of vested compensation and includes the usual attestation about undisclosed material information.

The Form 144 properly notes the nature of acquisition as restricted stock vesting and lists the broker and proposed exchange. The filer also discloses recent small sales in the prior three months. The disclosure meets procedural requirements and the attestation clause is present. Governance-wise, this appears as routine insider liquidity; no governance red flags or indications of undisclosed material events are stated in the form itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2383	18075.77	176690662	09/02/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			2383	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Fernando Madeira Rodrigues 155 E 44th Street, Floor 17 New York, NY 10017	Common	06/02/2025	2358	16175.88
Fernando Madeira Rodrigues 155 E 44th Street, Floor 17 New York NY 10017	Common	06/03/2025	4174	28842.34

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Teladoc Health (TDOC) Form 144 report?

The filing reports a proposed sale of 2,383 common shares acquired by restricted stock vesting with an aggregate market value of $18,075.77, to be sold through Fidelity on the NYSE.

Who is the seller and what recent sales are disclosed?

The filing lists prior June sales by Fernando Madeira Rodrigues totaling 6,532 shares for gross proceeds of $45,018.22.

How significant is the planned sale relative to outstanding shares?

The filing shows 176,690,662 shares outstanding, so the proposed sale of 2,383 shares is an immaterial fraction of the outstanding equity.

How were the shares acquired and paid for?

The securities were acquired on 08/29/2025 by restricted stock vesting and the nature of payment is listed as compensation.

Through which broker will the sale occur?

The notice names Fidelity Brokerage Services LLC and indicates the sale is to occur on the NYSE.